✉news ScienceBiology first seen 3 d ago, last 2 d ago, peak #10
NRG1 fusions and HER2 overexpression: same pathway, distinct biology
Original: NRG1 fusion vs HER2 overexpression: A shared pathway but distinct biology
Oncology discussions are contrasting NRG1 gene fusions with HER2 overexpression, two cancer drivers that activate the same ErbB signaling pathway but behave as biologically distinct entities. The comparison highlights that despite shared downstream signaling, the two alterations differ in their underlying biology, which has implications for how tumors are classified and how targeted therapies are selected for patients carrying each alteration.
Why now: Growing clinical interest in NRG1 fusions as a rare but actionable cancer driver is prompting comparisons with the well-established HER2-targeted treatment paradigm.
Rank over time, top of the chart is #1. 8 snapshots from 3 d ago to 2 d ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3793057